中文 | English
Return
Total: 41 , 1/5
Show Home Prev Next End page: GO
MeSH:(Trastuzumab/therapeutic use*)

1.Advances in Treatment of Human Epidermal Growth Factor Receptor 2-Positve Gastric Cancer.

Xiao-Qian WU ; Yu-Ping GE ; Xiao-Lei GONG ; Yuan LIU ; Chun-Mei BAI

Acta Academiae Medicinae Sinicae 2022;44(5):899-905

2.A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer.

Chun Xiao SUN ; Shu Sen WANG ; Jian Bin LI ; Yong Sheng WANG ; Qu Chang OUYANG ; Jin YANG ; Hai Bo WANG ; Xiao Jia WANG ; Wen Yan CHEN ; Peng YUAN ; Min YAN ; Ze Fei JIANG ; Yong Mei YIN

Chinese Journal of Oncology 2023;45(1):88-94

3.Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer.

Chinese Journal of Oncology 2022;44(9):913-927

4.Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients.

Yan SUN ; Li-qing LI ; San-tai SONG ; Li-gong XU ; Shi-ying YU ; Jin-wan WANG ; Ze-fei JIANG ; Ji-liang YIN ; Hui-hua XIONG

Chinese Journal of Oncology 2003;25(6):581-583

7.Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).

Yuanjia CHENG ; Hongyu XIANG ; Ling XIN ; Xuening DUAN ; Yinhua LIU

Chinese Medical Journal 2022;135(19):2311-2318

8.A real world study on the relationship between drug resistance of targeted therapy and prognosis of HER-2-positive advanced breast cancer.

Zi Jing WANG ; Yi Qun HAN ; Qiao LI ; Hong Nan MO ; Yi Qun LI ; Xiu Wen GUAN ; Yi Meng CHEN ; Shao Yan LIN ; Bing He XU ; Qing LI ; Pin ZHANG ; Fei MA

Chinese Journal of Oncology 2022;44(4):360-363

10.Development of antibody drugs targeting against HER2 for cancer therapy.

Qin TANG ; Qian DING ; Li LIN ; Zhen-zhen ZHANG ; Zheng DAI ; Jin-biao ZHAN

Acta Pharmaceutica Sinica 2012;47(10):1297-1305

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 41 , 1/5 Show Home Prev Next End page: GO